Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Endolife is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit. The busiest examiner for this portfolio is AFREMOVA, VERA, who is handling 1 pending office action.
The concentration of prosecution in 1 art unit and with 1 examiner suggests a specific technological focus for the company's current filings. With only 1 pending office action, the portfolio does not currently face a high volume of examiner interactions. Success in this area depends on addressing the specific concerns of the 1 examiner, as the portfolio lacks the breadth of multiple active examiners to average out prosecution timelines or difficulty levels. Practitioners should treat this 1 office action as a critical pivot point for the portfolio. The limited scope of 1 distinct examiner and 1 distinct art unit means that any feedback received will have a disproportionate impact on the company's overall patent position in this technology area. A successful outcome here would establish a baseline for future filings within the same Biotechnology & Pharmaceuticals domain.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260421 | USE OF DEOXYRIBONUCLEASE I IN THE TREATMENT OF ENDOMETRIOSIS IN PATIENTS WITH AN EPIGENETIC SIGNATURE OF ENDOMETRIOSIS ON CELL-FREE DNA | AFREMOVA, VERA | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260421 | USE OF DEOXYRIBONUCLEASE I IN THE TREATMENT OF ENDOMETRIOSIS IN PATIENTS WITH AN EPIGENETIC SIGNATURE OF ENDOMETRIOSIS ON CELL-FREE DNA | AFREMOVA, VERA | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260421 | USE OF DEOXYRIBONUCLEASE I IN THE TREATMENT OF ENDOMETRIOSIS IN PATIENTS WITH AN EPIGENETIC SIGNATURE OF ENDOMETRIOSIS ON CELL-FREE DNA | AFREMOVA, VERA | 1653 | §103§112 | Final Rejection | 31d overdue | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial